代谢疾病中免疫细胞与脂肪组织的交互作用:以1型糖尿病为重点
肥胖在1型糖尿病患者中日益普遍,脂肪组织功能失调与慢性低度炎症可能加剧胰岛素抵抗并促进自身免疫。本综述探讨肥胖相关脂肪组织适应不良如何影响1型糖尿病病理生理,并讨论新兴技术与精准医学在应对肥胖与1型糖尿病双重挑战中的潜力。
要点
- 脂肪组织已从能量储存库转变为代谢与免疫过程的关键调节者。
- 肥胖诱导的慢性低度炎症可能加剧胰岛素抵抗并促进针对胰岛β细胞的自身免疫。
- 连续葡萄糖监测与自动化胰岛素输注系统等新技术有望改善1型糖尿病合并肥胖患者的血糖管理与体重相关并发症。
核心结论
- 肥胖诱导的脂肪组织慢性低度炎症可能破坏全身免疫调节、促进胰岛素抵抗并可能增强针对胰腺β细胞的自身免疫。
- 应对肥胖与1型糖尿病的交互作用有助于重新界定研究重点和合并肥胖的1型糖尿病个体的管理策略。
研究设计与样本
- 综述:探讨肥胖中脂肪组织适应不良如何影响1型糖尿病的病理生理,讨论现有文献与知识空白,并强调弥补这些空白的重要性。
主要发现
- 脂肪组织曾被视为能量储存库,现已认识到是代谢和免疫过程的关键调节者。
- 全球肥胖患病率上升为1型糖尿病病理生理引入了探索不足的维度,对疾病发生、进展和管理有重要影响。
- 肥胖与1型糖尿病共存带来独特挑战,包括胰岛素抵抗加重和心血管疾病等并发症风险升高。
- 肥胖诱导的慢性低度炎症即「元炎症」在脂肪组织内形成促炎环境。
临床怎么用
- 连续葡萄糖监测和自动化胰岛素输注系统以及基因组学和代谢组学的见解正在革新糖尿病照护。
- 这些工具可加强血糖管理,并提供减轻体重相关并发症和个体化治疗策略的机会。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adipose tissue, once regarded merely as an energy reservoir, has emerged as a critical regulator of both metabolic and immune processes. This paradigm shift has profound implications for understanding and managing type 1 diabetes, a condition typically associated with lean individuals. The growing global prevalence of obesity has introduced an underexplored dimension to type 1 diabetes pathophysiology, a phenomenon that has significant consequences for disease development, progression and management. The coexistence of obesity and type 1 diabetes presents unique challenges, including exacerbation of insulin resistance and an elevated risk of complications such as CVD. Obesity-induced chronic low-grade inflammation, or 'meta-inflammation', creates a proinflammatory environment within adipose tissue. This disrupts systemic immune regulation, promotes insulin resistance and may even potentiate autoimmunity directed to pancreatic beta cells. Addressing these interactions will allow us to reframe research priorities and the management of type 1 diabetes in individuals who also live with obesity. In this review, we explore how adipose tissue maladaptation in obesity influences the pathophysiology of type 1 diabetes. We discuss existing literature and gaps in knowledge, and emphasise the importance of addressing these gaps. We also highlight the potential of emerging technologies and precision medicine to tackle the dual challenge of obesity and type 1 diabetes. Advances such as continuous glucose monitoring and automated insulin delivery systems and insights from genomics and metabolomics are revolutionising diabetes care. These tools can enhance glucose management and provide opportunities to mitigate weight-related complications and personalise treatment strategies.
引用
- Alzaid F, Fagherazzi G, Riveline JP, et al. Immune cell-adipose tissue crosstalk in metabolic diseases with a focus on type 1 diabetes. Diabetologia. 2025. PMID: 40553147. doi:10.1007/s00125-025-06437-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。